XHKG
0575
Market cap1mUSD
Jul 09, Last price
0.94HKD
1D
-1.05%
1Q
34.29%
Jan 2017
-92.03%
Name
Endurance RP Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Endurance RP Limited functions as an investment holding company, concentrating its investments within the healthcare and life sciences sectors across the People's Republic of China, Europe, Hong Kong, and Taiwan. The firm organizes its activities into two primary divisions: Biopharma and Corporate Investment. The Biopharma segment is responsible for the research, development, production, promotion, and distribution of pharmaceutical products aimed at addressing and managing urological disorders. This division also innovates artificial intelligence systems to precisely track the pace of aging, examining it at molecular, cellular, tissue, organ, systemic, physiological, and psychological levels. Through its Corporate Investment division, the company strategically invests in both publicly traded and privately held corporate entities. Additionally, it extends its services to include management consulting and corporate financial advice. Incorporated in 1991 and headquartered in Central, Hong Kong, Endurance RP Limited adopted its current name in June 2021, having previously operated as Regent Pacific Group Limited.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||